Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma.

Cancer patients often experience grief over lost health and lifestyle, with acceptance not always achieved. Personal ...

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

Participation in a structured exercise program following surgery and adjuvant chemo improved key survival end points in stage ...

Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and ...

The CheckMate 901 trial compared Opdivo-Yervoy with gemcitabine-carboplatin for cisplatin-ineligible metastatic urothelial carcinoma patients. Despite negative trial results, the FDA approved Opdivo ...

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell ...

Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when ...

Zepzelca Plus Tecentriq Boosts Survival in First-Line ES-SCLC Care ...

New treatment combinations are transforming genitourinary cancer care, improving survival and quality of life while ...

There is a mystical aspect about teddy bears in that they provide unconditional love. They are symbols of love. When a cancer ...